NASDAQ
QTTB
Last Price
US $18.46
KEY FIGURES
MKT CAP
$235.8M
EPS
TTM
$2.36
PEG
TTM
0.01x
P/E
TTM
7.83x
P/S
TTM
4.84x
YIELD
0.00%
GROWTH
Revenue Y/Y
Cash Flow (DCF)
Fair Value
Market $18.46
—
Default assumptions
EBITDA Multiple
Fair Value
Market $18.46
-32.12%
Default assumptions
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Q32 Bio Inc. cash flow to debt ratio of -218.61% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Q32 Bio Inc.'s free cash flow has increased -50.52% from $-67.79M last year to $-33.54M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Q32 Bio Inc.'s debt to equity ratio is 0.29, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Q32 Bio Inc.'s debt has decreased relative to shareholder equity from 3.33 last year to 0.29 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Q32 Bio Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Q32 Bio Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Q32 Bio Inc. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Q32 Bio Inc.'s short-term assets of $55.05M exceed its short-term liabilities of $11.35M
Increasing performance - ROA.
Q32 Bio Inc.'s return on assets of 52.21% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Q32 Bio Inc.'s return on equity of 230.68%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Q32 Bio Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Q32 Bio Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Q32 Bio Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Q32 Bio Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Q32 Bio Inc.'s yearly earnings has increased -162.47% since last year from $-47.73M to $29.82M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Q32 Bio Inc.'s yearly revenue has increased % since last year from $0.00 to $53.74M, signaling increasing performance
Increasing performance - ROIC.
ROIC 35.71% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Q32 Bio Inc.'s 3-year revenue CAGR of 100.66% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Q32 Bio Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Q32 Bio Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Q32 Bio Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Q32 Bio Inc. has an earnings yield of 12.78%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Q32 Bio Inc. is overvalued relative to its fair value price of 12.53 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Q32 Bio Inc. has an EV/EBITDA ratio of 6.48x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Q32 Bio Inc. has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
Q32 Bio Inc. has a price-to-book ratio of 5.62x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Undervalued - P/S ratio.
Q32 Bio Inc. has a price-to-sales ratio of 4.84x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
230.68%
Return on equity
ROIC: 35.71%
Valuation History
4.2X
Price to Earnings
EV/EBITDA: 4.8X
Cash flow
Profit margin
81.85%
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
23.93%
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $18.46
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.